Ipamorelin

What it is?

Ipamorelin is a selective growth hormone secretagogue studied for its ability to stimulate endogenous growth hormone (GH) release via ghrelin-receptor pathways. It is commonly positioned for protocols targeting recovery, body composition, and sleep-related regeneration, with an emphasis on a cleaner signalling profile versus broader secretagogues.

Dripfy Advantage

• Receptor engagement: Acts primarily through growth hormone secretagogue receptor (GHSR-1a) signalling to promote GH release.
• Selectivity profile: Positioned as a more selective secretagogue, with research use often highlighting limited activation of prolactin- and cortisol-associated pathways.
• Pulsatile GH dynamics: Supports pulsatile GH release patterns, aligning more closely with physiological secretion rhythms rather than continuous stimulation.
• Downstream cascade alignment: By increasing endogenous GH signalling, it is associated with downstream effects on IGF-1 axis activity and recovery-related anabolic pathways.
• Recovery–sleep interface: Frequently positioned in protocols where sleep architecture and recovery kinetics are relevant endpoints.

Clinical Applications & Therapeutic Potential

• Endogenous GH axis support: Increased GH pulse signalling with downstream endocrine pathway activation relevant to adaptation models.
• Body composition endpoints: Support for fat-loss signalling while preserving lean-mass markers in structured diet and training contexts.
• Recovery kinetics: Improved recovery-related signalling following training stress, including reduced perceived fatigue markers in observational protocols.
• Sleep quality indices: Association with improved sleep-depth markers and next-day recovery readiness endpoints (protocol-dependent).

Composition & Formulation

• Peptide content: 5 mg CJC-1295 No DAC + 10 mg Ipamorelin
• Vehicle: Proprietary pH-balanced buffer solution
• Delivery system: Pre-filled, multi-dose, closed-system pen
• Total volume: 3 mL
• Purity: ≥99% for both peptides by HPLC/MS